Cross-topic event
RASolute 302 in NEJM and ASCO plenary: daraxonrasib median OS 13.2 vs 6.7 months in second-line metastatic pancreatic cancer
May 31, 2026
Sciencedesk view
RASolute 302 in NEJM and ASCO plenary: daraxonrasib median OS 13.2 vs 6.7 months in second-line metastatic pancreatic cancer
Per Dana-Farber, Revolution Medicines, and Science News (May 31, 2026), global randomized open-label Phase 3 RASolute 302 (NCT06625320) results were presented a…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
NEJM Phase 3: Oral Daraxonrasib Nearly Doubles Median Survival in Treated Metastatic Pancreatic Cancer
Per CBS News, NEJM, and TPR on May 31, 2026, the RASolute 302 trial (Revolution Medicines–funded) randomized 500 patients with previously treated mPDAC to daily…
READ THE DAY'S DIGEST →
Jun 1, 2026
Sciencedesk view
RASolute 302 keeps dominating headlines: daraxonrasib median OS 13.2 vs 6.7 months in second-line mPDAC
Per ScienceAlert (AP), ABC News, and Revolution Medicines (June 1, 2026), global randomized Phase 3 RASolute 302 (NCT06625320) results continue to reverberate a…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
Oral daraxonrasib: median survival 13.2 months in pretreated metastatic pancreatic cancer vs. ~6.7 on chemo
Per ScienceAlert and the NEJM (widely reported June 1, 2026, after ASCO weekend release), the RASolute 302 phase 3 trial randomized 500 patients with previously…
READ THE DAY'S DIGEST →